<DOC>
	<DOCNO>NCT00054678</DOCNO>
	<brief_summary>The MyoCell™ implantation use MyoCath™ delivery catheter system may potential add new dimension management post-infarct deterioration cardiac function subject congestive heart failure . Based pre-clinical study , implantation autologous skeletal myoblasts may lead replacement non-functioning myocardial scar function muscle improvement myocardial performance . Preliminary data human subject suggest skeletal myoblast implantation time CABG may lead effect . In principal , myoblast implantation catheter delivery may offer therapeutic benefit . The present clinical study conduct primarily evaluate safety MyoCell™ implantation use MyoCath™ delivery system secondarily evaluate effect regional myocardial function post treatment .</brief_summary>
	<brief_title>MYOHEART™ ( Myogenesis Heart Efficiency Regeneration Trial )</brief_title>
	<detailed_description>A promising approach reversal stabilization post-infarct remodel process direct injection regenerative cell myocardial infarct scar . Such cell-based therapy cardiac repair call `` cellular cardiomyoplasty '' . The MyoCell™ implantation use MyoCath™ delivery catheter system may potential add new dimension management post-infarct deterioration cardiac function subject congestive heart failure . MyoCath™ Bioheart 's proprietary catheter delivery system develop Bioheart facilitate MyoCell™ delivery myocardium via retrograde catheterization leave ventricular cavity . Based pre-clinical study , implantation autologous skeletal myoblasts may lead replacement non-functioning myocardial scar function muscle improvement myocardial performance . Preliminary data human subject suggest skeletal myoblast implantation time CABG via endoventricular approach may lead effect . In principle , myoblast implantation catheter delivery may offer therapeutic benefit . The present clinical study conduct primarily : 1 . Assess safety effect myocardial function MyoCell™ ( autologous skeletal myoblast ) use dose escalation methodology follow implantation myocardial scar tissue subject congestive heart failure experience previous myocardial infarction ( ) implantable cardioverter defibrillator ( ICD ) previously implant . Safety endpoint evaluation nature frequency Adverse Events 12-month period follow MyoCell™ treatment . 2 . To assess safety feasibility use transendocardial injection catheter ( MyoCath™ ) system deliver MyoCell™ myocardial scar tissue subject congestive heart failure experience previous myocardial infarction ( ) implantable cardioverter defibrillator ( ICD ) previously implant . Catheter performance assess time implantation use clinical evaluation questionnaire . Safety endpoint evaluation nature frequency Adverse Events time implantation Day 14 follow-up visit . If patient meet baseline enrollment criterion , approximately 5-10 gram skeletal muscle obtain subject 's leg muscle myoblast isolation expansion vitro ( MyoCell™ ) specify site cGMP culture laboratory . The expand myoblast cell , MyoCell™ implant akinetic myocardial scar region previous infarct utilize Bioheart 's MyoCath™ transendocardial delivery catheter system . The MyoCath™ endoventricular device expect deliver MyoCell™ autologous skeletal myoblast cell scar myocardial region steer catheter contains retractable hypodermic needle target site implantation . This dose escalation study 4 cohort group consist 5 patient . A report 1 month safety data cohort present Data Safety Monitoring Board permission go next high dosage . In first cohort dose escalation study , 2 injection perform ; second cohort , 6 injection ; third cohort , 18 injection ; fourth cohort , 27 injection , depend size infarct scar , inject entire myocardial infarct scar akinetic area . The entire study expect complete first half 2007 , include complete enrollment well 12-month follow-up last subject .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Patients meet follow inclusion criterion none exclusion criterion enrol clinical study . Defined region myocardial dysfunction relate previous myocardial infarction ( ) involve anterior , lateral , posterior inferior wall , &gt; 12 week ( 84 day ) old scheduled time MyoCell™ implantation Patients prior placement Implantable Cardioverter Defibrillator ( ICD ) must place least one month ( 30 day ) prior MyoCell™ implantation New York Heart Association ( NYHA ) Symptom Class II III optimal medical therapy Age &gt; 30 &lt; 80 year old Need revascularization rule coronary angiogram noninvasive stress test within six month ( 180 day ) screen Able undergo surgical biopsy skeletal muscle successful culture harvest myoblasts Target region wall thickness &gt; 6 mm Echocardiography Left ventricular ejection fraction &gt; 20 % &lt; 40 % Radionuclide Ventriculography Left Ventricular Angiography screen Able give write informed consent Able walk minimum distance 300 meter 6minute walk test Myocardial infarction within 12 week ( 84 day ) prior investigational procedure New York Heart Association Symptom Class I IV Coronary Artery Bypass Grafting ( CABG ) within 3 month ( 90 day ) prior schedule MyoCell™ implantation Percutaneous Coronary Intervention ( PCI ) within 6 month ( 180 day ) prior MyoCell™ implantation Canadian Heart Classification angina &gt; Class II unstable angina Any cardiac valve replacement Heart failure secondary valvular disease Aortic stenosis great mild degree Left ventricular atrial mural thrombus Chronic pulmonary disease Atherosclerosis and/or tortuosity aorta , iliac femoral artery degree , judgment principal investigator , would impede preclude safe retrograde passage 8FR MyoCath™ delivery catheter History severe radiocontrast reaction Known sensitivity gentamicin sulfate and/or amphotericinB Previous angiogenic therapy and/or myocardial laser therapy Exposure investigational drug procedure within 1 month prior study entry The use expect use antineoplastic drug history cancer within 5 year , except basal cell carcinoma skin Skeletal muscle disease , either primary ( i.e. , myopathy ) secondary ( i.e. , ischemic ) underlie myopathy myasthenia gravis , muscular dystrophy , etc . determine board certify pathologist examine sample patient muscle biopsy Serum creatinine &gt; 2.5 mg/dL end stage renal disease Prostate Specific Antigen ( PSA ) suggestive carcinoma prostate ( i.e. , &gt; 4.0 ng/mL ) Carcinoembryonic Antigen ( CEA ) &gt; 5.0 ng/mL end stage renal disease Active infectious disease and/or know test positive HIV , HTLV , HBVsAg , HCV , CMV and/or syphilis . If panel include antibody HBc HBVsAg , expert consult patient eligibility base patient 's infectious status Females pregnant nursing Females childbearing potential unwilling maintain contraceptive therapy duration study Morbid obesity 100 pound ideal body weight Body Mass Index ( BMI ) &gt; 40 Any illness might affect patient 's survival study 12 month followup period* Any illness , Investigator 's judgment , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result No write Informed Consent unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Heart disease</keyword>
	<keyword>Endoventricular</keyword>
	<keyword>Cardiovascular</keyword>
	<keyword>Interventional</keyword>
	<keyword>ICD</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Implantable Cardioverter Defibrillator</keyword>
</DOC>